Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high expectations from early-phase studies, the drug initially did not meet the ...
Researchers have now found a substance that effectively combats glioblastomas, at least in the laboratory: an antidepressant ...
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...